Wait and see for AstrazenicaThe price could go either way depending on the results from clinical trials of their Covid-19 vaccine.. so watch this space for confirmation either way.
Vaccine
Bullish outlook for ModernaI am looking for a breath through of resistance, followed by confirmation that the resistance becomes support as a signal to buy the next bull run for Moderna on the daily time frame.
GOLD AUGUST 17 TH - 21ST REVIEWHELLO TRADERS!
QUITE THE BUSY TRADING WEEK THIS WEEK WITH A HUGE SELL OFF IN GOLD.
WE NOW ARE IN THE CORRECTIVE MOVE TO THE UPSIDE INTO NEXT WEEK.
WE SEE GOLD RETEST OF $2,000 LEVELS LIKELY AND WE WILL SEE WHAT HAPPENS
FROM THERE.
HAVE A GREAT WEEKEND ALL!
HAPPY TRADING!
THE TRADING REGIME!
S&P 500 Index - SP500 - Major reversal is near!S&P 500 index is approaching reversal level
perhaps around 3500 level.
The expected sharp reversal may take
the Index to as low as 1800 area as shown.
Vaccine!CoronaVirus vaccine approval will be the most explosive event ever happened on the planet. Anyone who tells you otherwise is a stupid or a liar, if not both.
The best investment strategy now is to create a strategy around the vaccine development. That doesn't mean to buy biotechnology stocks. Simply put -
Stocks that plunged because of the Virus will rally because of the Vaccine. Stay woke!.
[NVAX] Novavax: Preliminary studies produce promising resultsPreliminary studies on coronavirus vaccines have produced promising results.
I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will hopefully pave the way for vaccines going forward.
Things to watch even after COVID-19:
- NanoFlu™
- ResVax™
- Recombinant Nanoparticle Vaccine Technology
- Matrix-M™ Adjuvant Technolog
TL;DR - To the moon and (probably) back lol
*Note: This is pure speculation and my own opinion*
NY Times: www.nytimes.com
CNBC: www.cnbc.com
SPY:Does it know where it will go?This week won't be complete with some volatility because of unemployement rates,vaccine news and also elections. SPY has gaps to fill on upside and also downside. Down it has to go to 320.20,up to 325.11. 321.28 seems to be where things are bouncing PM so that would be a good level to watch. If we go bellow then 320.20 will be for sure there as well to fill the gap.
Any opinions on this chart will be gladly appeciated! Stay safe and happy trading!
Top Coronavirus Trading Ideas for StocksStocks did not get too much of a boost from the FOMC event yesterday, unlike other assets. Right now, the S&P is still hovering between the range we have been watching for a while now, between 3200, a technical, psychological, and Fibonacci level, and 3280, a relative high and Fibonacci level. However, Ghostsquawk's risk sentiment analysis is picking up some risk on sentiment this morning. A lot of companies seem to be reporting earnings beats and price upgrades, like Yum Brands, Comcast, and Molson Coors. Additionally Johnson and Johnson claims to have some success with a Coronavirus vaccine, so that should give stocks a brief lift, whether the claim stands or not. Keep your eye on 3200 for a possible long entry.
Pfizer great news!! and resistance break!Some great vaccine news as US prepares to vaccinate the American population with 100M doses worth up to 2Billion USD and supplied by Pfizer and BioNtech!. The resistance line that PFE was under represents a long term hard resistance since 2018. PFE might go a lot higher now, perhaps as high as Moderna.
NVAX'S VACCINE FOR FLU IS PROMISING! Hello traders!
Good news from Novavax! The chances of approval for flu vaccine candidate NanoFlu seems actually quite good!
Moreover, if we look at the chart, we can see that the price is on a strong uptrend that doesn't seem to want to stop. The bullish momentum is still strong!
Remember to put a stop loss in order to secure your capital!
Not a financial advice.
Enjoy your trade!
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients.
On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%.
The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it.
On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish
Volume, Bullish
PMO, Bullish
MACD, Bullish
RSI, Bullish
OBV, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
$MRNA WatchYet another potentially profitable play regarding the Covid-19 pandemic is $MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
[NVAX] Novavax: Update - 1.6 billion funded!I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked.
Today's News:
1. www.cnbc.com
2. www.fool.com
ABC has scored analyst upgrades heading into JulyFinally, coronavirus vaccines and treatments should serve as a tailwind for the health care industry as a whole. Hardy is projecting mid-single-digit earnings growth over the long term, including 9% earnings per share growth in fiscal 2020. CFRA has a "strong-buy" rating and a $109 price target for ABC stock.
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one.
This is purely speculation based on their pipeline. This is not financial advice.
Covid funding p&dThis company has not done anything noteworthy for the last few years. They were able to get funding from the European International Bank to work on COVID related solutions released in 3 tranches. The likely outcome is they will not make enough progress to unlock the future tranches. Seems to me like they are just grabbing the handout and will resume their normal downtrend in the long term.
